From: Systematic review of circulating MICRORNAS as biomarkers of cervical carcinogenesis
CONTROL GROUP (C) | CIN GROUP (CIN) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Author | Year | Country | N | Mean Age (y) | HPV tested | HPV detection method | HPV infection | HPV type | N | Mean Age (y) | HPV tested | HPV detection method |
Liu; Xin; Ma [11] | 2015 | China | 50 | N/I | No | N/A | N/A | N/A | T: 86 CIN I: 19 CIN II: 25 CIN III: 42 | N/I | N/I | N/I |
Zhang et al [8] | 2015 | China | 193 | N/I | N/I | N/I | N/I | N/I | 186 | N/I | N/I | N/I |
Nagamitsu et al [12] | 2016 | Japan | 31 | 39 | N/I | N/I | N/I | N/I | T: 55 CIN I: 15 CIN II: 16 CIN III: 24 | CIN I: 34 CIN II: 35 CIN III: 34 | N/I | N/I |
Sun et al [13] | 2016 | China | 32 | N/I | N/I | N/I | N/I | N/I | 13 | N/I | N/I | N/I |
Kong et al [14] | 2017 | China | 40 | 39 | Yes | Liquid-Based Cytology | N/I | N/I | T: 68 CIN I: 21 CIN II: 23 CIN III: 24 | 39 | Yes | Liquid-Based Cytology |
Wei; Wen-Ming; Jun-Bo [15] | 2017 | China | 120 | N/I | N/I | N/I | N/I | N/I | 120 | N/I | N/I | N/I |
Wang et al [16] | 2018 | China | 50 | N/I | N/I | N/I | N/I | N/I | HSIL: 50 LSIL: 50 | N/I | N/I | N/I |
Farzanehpour et al [17] | 2019 | Iran | 36 | 36 | Yes | PCR | Yes | 16 66 68 | 18 | 47 | Yes | PCR |
Wang et al [18] | 2019 | China | 42 | 40.94 | Yes | N/I | No | N/A | T: 144 CIN I: 19 CIN II: 54 CIN III: 71 | CIN I: 41.93 CIN II: 42.37 CIN III: 40.77 | N/I | N/I |
Yang; Zhang [19] | 2019 | China | 50 | 43 | Yes | N/I | No | N/A | T: 50 CIN I: 15 CIN II: 15 CIN III: 20 | CIN I: 38.0 CIN II: 35.3 CIN III: 36.2 | Yes | N/I |
Zheng et al [20] | 2019 | China | 50 | 50 | N/I | N/I | N/I | N/I | T: 90 CIN I: 34 CIN II-III: 56 | 50 | N/I | N/I |
Zheng et al [21] | 2020 | China | 41 | 42.71 | N/I | N/I | N/I | N/I | 40 | 43.88 | N/I | N/I |
Qiu et al [22] | 2020 | China | 90 | > = 50: 41 < 50: 49 | N/I | N/I | N/I | N/I | 45 | > = 50: 20 < 50: 25 | N/I | N/I |
Aftab et al [23] | 2021 | Índia | 50 | N/I | Yes | PCR | Yes | 16: 2 | LSIL: 17 HSIL: 33 | N/I | Yes | PCR |
Hoelzle et al [24] | 2021 | Brasil | 12 | 27,5 | Yes | PCR | No | N/A | LSIL: 14 HSIL: 11 | LSIL: 32 HSIL: 39 | Yes | PCR |
Ocadiz-Delgado et al [25] | 2021 | México | 23 | 38 | Yes | PCR | No | N/A | 17 | 34 | Yes | PCR |
Yamanaka et al [26] | 2021 | Japão | 34 | 42 | N/I | N/I | N/I | N/I | 64 | CIN I: 34 CIN II: 35 CIN III: 34 | N/I | N/I |
CIN GROUP (CIN) | CERVICAL CANCER GROUP (CC) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Author | HPV infection | HPV type | N | Mean Age (y) | Tumor stage | Metast | HPV tested | HPV detection method | HPV infection | HPV type | Specim. |
Liu; Xin; Ma [11] | N/I | N/I | 105 | <= 50: 64 > 50: 41 | FIGO I-II: 74 III-IV: 31 | Yes: 37 No: 68 | Yes | N/I | Yes: 92 No: 13 | N/I | Serum |
Zhang et al [8] | N/I | N/I | 184 | N/I | N/I | N/I | N/I | N/I | N/I | N/I | Serum |
Nagamitsu et al [12] | N/I | N/I | 45 | 49 | Ia: 7 Ib: 16 IIa: 7 IIb: 10 III: 3 IV: 2 | N/I | N/I | N/I | N/I | N/I | Serum |
Sun et al [13] | N/I | N/I | 40 | <= 60: 22 > 60: 18 | Stage I: 12 Stage II, III and IV: 28 | Yes: 29 No: 11 | Yes | N/I | Yes: 28 No: 12 | N/I | Serum |
Kong et al [14] | Yes (all) | N/I | 18 | 39 | FIGO Ia - IIa | N/I | Yes | Liquid- Based Cytology | Yes (all) | N/I | Serum |
Wei; Wen-Ming; Jun-Bo [15] | N/I | N/I | 120 | < 50: 59 > = 50: 61 | FIGO I-II: 77 III: 43 | Yes: 47 No: 73 | Yes | N/I | Yes: 81 No: 39 | N/I | Plasma |
Wang et al [16] | N/I | N/I | 50 | N/I | N/I | N/I | N/I | N/I | N/I | N/I | Serum |
Farzanehpour et al [17] | Yes | 16 53 | 18 | 61 | N/I | N/I | Yes | PCR | Yes | 16 | Serum |
Wang et al [18] | N/I | N/I | 15 | 49.73 | N/I | N/I | N/I | N/I | N/I | N/I | Plasma |
Yang; Zhang [19] | No | N/A | 50 | 48 | Stage I: 15 Stage II: 15 Stages III – IV: 20 | N/I | Yes | N/I | No | N/A | Total Blood |
Zheng et al [20] | N/I | N/I | 63 | 50 | N/I | N/I | N/I | N/I | N/I | N/I | Exosomes |
Zheng et al [21] | N/I | N/I | 40 | 50.39 | FIGO I B1– I B2: 26 II A1– II B2: 12 N/I: 2 | Yes: 9 No: 25 N/I: 6 | N/I | N/I | N/I | N/I | Serum |
Qiu et al [22] | N/I | N/I | 112 | > = 50: 53 < 50: 59 | I: 90 IIA:22 | Yes: 20 No: 92 | N/I | N/I | N/I | N/I | Serum |
Aftab et al [23] | Yes | 16 LSIL: 4 HSIL: 24 | 50 | N/I | I: 10 II: 17 III: 18 IV: 5 | N/I | Yes | PCR | Yes | HG 16: 37 CS 16: 40 18: 2 | Urine |
Hoelzle et al [24] | Yes | LSIL 33: 2 Outros: 3 HSIL 16: 3 31: 1 Outros: 3 | 13 | 47 | N/I | N/I | Yes | PCR | Yes | 16: 4 18: 2 33: 2 Outros: 4 | Plasma |
Ocadiz-Delgado et al [25] | Yes | 16 | 23 | 50 | N/I | N/I | Yes | PCR | Yes | 16 | Serum |
Yamanaka et al [26] | N/I | N/I | 46 | 49 | FIGO IA: 4 IB: 21 IIA: 4 IIB: 10 III: 3 IV: 4 | Yes: 19 No: 16 N/I: 11 | N/I | N/I | N/I | N/I | Serum |